{"url_path":"/sec/stok/8-k/2026-06-30/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001193125-26-289409-index.html","accession_number":"0001193125-26-289409","cik":"0001623526","ticker":"STOK","issuer_name":"Stoke Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001193125-26-289409-index.html","primary_entity_key":"0001623526","primary_entity_name":"Stoke Therapeutics, Inc."},"word_count":115,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nAs noted in the Press Release, enrollment of 162 patients into the EMPEROR study has now completed in the planned primary analysis population across the U.S., U.K., and Japan. A Phase 3 data readout from these patients is anticipated in the third quarter of 2027. Approximately 50 of these patients are through 28 weeks of treatment, the time point at which the primary endpoint of change in major motor seizure frequency is measured. The Company plans to initiate a rolling New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration in the first quarter of 2027 and expects completion of the NDA submission in the second half of 2027."}